{"schema_version":"secwatch.filing_event.v1","accession":"0001688757-24-000056","form_type":"8-K","ticker":"ESTA","cik":"0001688757","company_name":"ESTABLISHMENT LABS HOLDINGS INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.588683+00:00","generated_at":"2026-06-02T11:11:21.750310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Establishment Labs reports Q1 revenue down 20% YoY; narrows operating loss sequentially; reaffirms 2024 guidance","bullets":["Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.","Adjusted EBITDA loss improved to $3.7M from $17.3M in Q4 2023; operating loss $8.8M vs $22.1M in Q4 2023.","Cash balance $73.0M, up $32.9M from Dec 31, 2023 due to private placement; 2024 revenue guidance reaffirmed at $174M-$184M.","Company presented 4-year Motiva US IDE study data with low capsular contracture/rupture rates; expects FDA approval in 2024.","Launched Motiva implants in China and Flora tissue expander in US; cost reduction initiatives lowered SG&A and R&D expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001688757-24-000056","json":"https://secwatch.observer/filing/0001688757-24-000056.json","markdown":"https://secwatch.observer/filing/0001688757-24-000056.md","text":"https://secwatch.observer/filing/0001688757-24-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/0001688757-24-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/esta-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:11:21.750310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f7842dcc37176d92868b1793cc61daf898d2f73","claim":"ESTABLISHMENT LABS HOLDINGS INC. reported the three months ended March 31, 2024 results: revenue $37.2 million, net income $16.2 million. Guidance reaffirmed.","evidence_excerpt":"and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook • First quarter worldwide revenue of $37.2 million. • 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants ® in the United States,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/0001688757-24-000056-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$37.2 million"},{"label":"Net income","value":"$16.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}